Urate-lowering effects of dipeptidyl peptidase-4 inhibitors

Hyperuricemia is an increase of uric acid (UA) concentration in blood serum >420 pmol/L in men or >360 pmol/L in women and is considered to be a common biochemical abnormality. This condition shows that the extracellular fluid is oversaturated with urates, which concentration exceeds the limit of their solubility. This fact predisposes to the formation of crystals of sodium salt of UA and results in gout, urolithiasis, and other diseases. The frequent combination and relationship between purine and carbohydrate metabolism were noted in previous studies. In this regard, the choice of drugs for correcting these disorders should consider the possibility of a combined positive effect on the UA and serum glucose levels. The hypoglycemic drugs with pleiotropic effects on several metabolic syndrome components are considered to be of particular interest. Currently, one of the most frequently prescribed groups of drugs in the treatment of diabetes mellitus type 2 are dipeptidyl peptidase-4 inhibitors, which affect the level of incretins (gliptins). These drugs can be potentially attractive in patients with purine metabolism disorders since the available data indicate that these drugs affect UA level.

1. Zhelyabina OV, Eliseev MS. Xanthine oxidase inhibitors in asymptomatic hyperuricemia. Modern rheumatologyjournal. 2019;13(4):137-142. (In Russ.) doi: https://doi.org/10.14412/1996-7012-2019-4-137-142

2. Shiozawa A, Szabo SM, Bolzani A, et al. Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 2017;44(3):388-396. doi: https://doi.org/10.3899/jrheum.160452

3. Abbasian M, Ebrahimi H, Delvarianzadeh M, et al. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016;10(3):132-136. doi: https://doi.org/10.1016/j.dsx.2016.01.003

4. Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207. doi: https://doi.org/10.1186/s12872-016-0379-z

5. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2019;79(1):31-38. doi: https://doi.org/10.1136/annrheumdis-2019-215315

6. Eliseev MS. Podagra. In: Nasonov EL. Revmatologiya. Rossiyskiye klinicheskiye rekomendatsii. Moscow: GEOTAR-Media; 2017. P 253-264. (In Russ.)

7. Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformine on the clinical course of gout and insulin resistance. Clinical medicine. 2009;87(7):41-46. (In Russ.)

8. Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic archive. 2020;92(5):110-118. (In Russ.) doi: https://doi.org/10.26442/00403660.2020.05.000633

9. Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of Type 2 diabetes: a prospective study. Am J Med. 2010;123(10):957-961. doi: https://doi.org/10.1016/j.amjmed.2010.03.027

10. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi: https://doi.org/10.1002/art.22466

11. Eliseev MS, Barskova VG. Carbohydrate metabolic disturbances in gout: Detection rate and clinical features. Therapeutic Archive. 2010;82(5):50-54. (In Russ.)

12. Choi BG, Kim DJ, Baek MJ, et al. Hyperuricaemia and development of type 2 diabetes mellitus in Asian population. Clin Exp Pharmacol Physiol. 2018;45(6):499-506. doi: https://doi.org/10.1111/1440-1681.12911

13. Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: https://doi.org/10.1186/1471-2369-15-122

14. Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with Type 2 diabetes mellitus. PLoSONE. 2011;6(11):e27817. doi: https://doi.org/10.1371/journal.pone.0027817

15. Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197-3204. doi: https://doi.org/10.1096/fj.13-247148

16. Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145-4151. doi: https://doi.org/10.2174/138161205774913255

17. Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69(6):1036-1044. doi: https://doi.org/10.1161/hypertensionaha.116.08998

18. Fonseca VA. Defining and characterizing the progression of Type 2 diabetes. Diabetes Care. 2009;32(suppl_2):S151-S156. doi: https://doi.org/10.2337/dc09-s301

19. Zhang Y, Wei F, Chen C, et al. Higher triglyceride level predicts hyperuricemia: A prospective study of 6-year follow-up. J Clin Lipidol. 2018;12(1):185-192. doi: https://doi.org/10.1016/jJacl.2017.10.009

20. Eliseev MS, Nasonov EL.Therapy with canakinumab for gout. Rheumatology science and practice. 2018;56:41-48. (In Russ.). doi: https://doi.org/10.14412/1995-4484-2018-41-48

21. Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study. Ann Rheum Dis. 2014;74(9):1651-1658. doi: https://doi.org/10.1136/annrheumdis-2014-205337

22. Rodrfguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis. 2010;69(12):2090-2094. doi: https://doi.org/10.1136/ard.2010.130013

23. Chen W, Liu X, Ye S. Effects of metformin on blood and urine proinflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34. doi: https://doi.org/10.1186/s12950-016-0142-3

24. Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656

25. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197-201. doi: https://doi.org/10.1007/bf00577838

26. Lambeir AM, Durinx C, Scharpe S, de Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294. doi: https://doi.org/10.1080/713609354

27. Deacon CF. Therapeutic Strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181-2189. doi: https://doi.org/10.2337/diabetes.53.9.2181

28. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP Gastroenterology. 2007;132(6):2131-2157. doi: https://doi.org/10.1053/j.gastro.2007.03.054

29. Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25(8):1963-1972. doi: https://doi.org/10.1185/03007990903094361

30. Yamauchi K, Sato Y, Yamashita K, et al. RS3PE in association with dipeptidyl peptidase-4 Inhibitor: report of two cases. Diabetes Care. 2012;35(2):e7. doi: https://doi.org/10.2337/dc11-1995

31. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with Type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2012;36(2):237-244. doi: https://doi.org/10.2337/dc12-0706

32. Weihofen WA, Liu J, Reutter W, et al. Crystal Structure of CD26/Dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem. 2004;279(41):43330-43335. doi: https://doi.org/10.1074/jbc.m405001200

33. Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem. 1995;270(32):18797-18803. doi: https://doi.org/10.1074/jbc.270.32.18797

34. Itou M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298-2306. doi: https://doi.org/10.3748/wjg.v19.i15.2298

35. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-838. doi: https://doi.org/10.1172/jci34275

36. Ismailova GA. Vliyanie ingibitorov dipeptidilpeptidazy-4 na pokazateli lipidnogo obmena u patsientov s sakharnym diabetom 2-go tipa v sochetanii s metabolicheskim sindromom. Kardiologiya vBelarusi. 2016;(1):138-147. (In Russ.)

37. Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017;59(1):R1-R10. doi: https://doi.org/10.1530/jme-17-0005

38. Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology. 2014;155(6):2266-2276. doi: https://doi.org/10.1210/en.2013-1920

39. Stange T, Kettmann U, Holzhausen HJ. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur J Histochem. 2000;44(2):157-164.

40. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207. doi: https://doi.org/10.1007/s11154-014-9287-7

41. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl saltsensitive rats. J Hypertens. 2003;21(6):1 125-1135. doi: https://doi.org/10.1097/00004872-200306000-00012

42. Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. MicrovascRes. 2012;84(3):395-398. doi: https://doi.org/10.1016/j.mvr.2012.06.008

43. Kusunoki M, Natsume Y, Miyata T, et al. Effects of concomitant administration of a Dipeptidyl Peptidase-4 inhibitor in Japanese patients with Type 2 diabetes showing relatively good glycemic control under treatment with a sodium glucose CoTransporter 2 inhibitor. Drug Res (Stuttg). 2018;68(12):704-709. doi: https://doi.org/10.1055/a-0585-0145

44. Conlon BA, Law WR. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol. 2004;138(1):14-20. doi: https://doi.org/10.1111/j.1365-2249.2004.02591.x

45. Klemann C, Wagner L, Stephan M, von Horsten S. Cut to the chase: a review of CD26 / dipeptidyl peptidase-4’ s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21. doi: https://doi.org/10.1111/cei.12781

46. Lin CH, Lin CC. Sitagliptin attenuates inflammatory responses in lipopolysaccharide - stimulated cardiomyocytes via nuclear factor-kB pathway inhibition. Exp TherMed. 2016;11(6):2609-2615. doi: https://doi.org/10.3892/etm.2016.3255

47. Kabel AM, Omar MS, Alhadhrami A, et al. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-P1, NF-kB and glucagon-like peptide 1. PhysiolBehav. 2018;188:108-118. doi: https://doi.org/10.1016/j.physbeh.2018.01.028

48. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;19(1):133-140. doi: https://doi.org/10.1517/13543780903463862

49. Heise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-794. doi: https://doi.org/10.1111/j.1463-1326.2009.01046.x

50. Yamagishi S, Ishibashi Y, Ojima A, et al. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol. 2014;176(2):550-552. doi: https://doi.org/10.1016/jjjcard.2014.07.023

51. Darsalia V, Ortsater H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2012;62(4):1289-1296. doi: https://doi.org/10.2337/db12-0988

52. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119-130. doi: https://doi.org/10.1159/000341487

53. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014;46(10):717-721. doi: https://doi.org/10.1055/s-0034-1371892

54. Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. JHypertens. 2014;32(11):2211-2223. doi: https://doi.org/10.1097/hjh.0000000000000328

55. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120-2131. doi: https://doi.org/10.2337/db13-1029

56. Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90(4):783-796. doi: https://doi.org/10.1016/j.kint.2016.06.012

57. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA. 2019;321(1):69-79. doi: https://doi.org/10.1001/jama.2018.18269

58. McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with Type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139(3):351-361. doi: https://doi.org/10.1161/circulationaha.118.038352

59. Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in Type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304-2310. doi: https://doi.org/10.2337/dc16-1415

60. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10):1171-1178. doi: https://doi.org/10.1177/0091270008323753